{"paper_id":"450d81ea-c739-49a8-9b7f-e0fef7fcea57","body_text":"Abstract\nPurpose\nTo evaluate the relationship between endometriosis and polymorphisms in the genes encoding tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), TRAIL receptor (DR) and osteoprotegerin (OPG) and their serum levels in Korean women.\nMethods\nA case–control study was conducted with 138 women with endometriosis and 214 women without endometriosis in academic medical center. TRAIL c.49G>A, c.592A>G, c.615A>G, and c.662T>C; DR4 c.626G>C and c.1322A>G; DR5 c.95C>T, c.200C>T, and c.72T>G; OPG −245T>G, c.9C>G, c.788A>C, and c.9938G>T polymorphisms were investigated and circulating levels of TRAIL and OPG were measured.\nResults\nThe TRAIL c.49G>A, c.615A>G, and c.662T>C; the DR4 c.626G>C; the DR5 c.72T>G; the OPG c.788A>C and c.9938G>T polymorphisms were not observed. The genotype distributions and allele frequencies of single or combined polymorphisms of TRAIL, DR4, DR5, and OPG measured in women with endometriosis were not different from those in women without endometriosis, regardless of endometriosis stage. Serum TRAIL and OPG levels were significantly lower in women with endometriosis than in women without endometriosis, but these levels did not show differences between early and advanced endometriosis.\nConclusions\nEndometriosis is associated with circulating TRAIL and OPG levels in Korean women but not with the TRAIL, DR, and OPG polymorphisms.\nSimilar content being viewed by others\nReferences\nMathur SP (2000) Autoimmunity in endometriosis: relevance to infertility. Am J Reprod Immunol 44(2):89–95\nSimpson JL, Bischoff FZ, Kamat A, Buster JE, Carson SA (2003) Genetics of endometriosis. Obstet Gynecol Clin North Am 30(1):21–40 vii\nTempfer CB, Simoni M, Destenaves B, Fauser BC (2009) Functional genetic polymorphisms and female reproductive disorders: part II–endometriosis. Hum Reprod Update 15(1):97–118. doi:10.1093/humupd/dmn040\nGarcia-Velasco JA, Arici A (2003) Apoptosis and the pathogenesis of endometriosis. Semin Reprod Med 21(2):165–172. doi:10.1055/s-2003-41323\nGaur U, Aggarwal BB (2003) Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol 66(8):1403–1408\nBersinger NA, von Roten S, Wunder DM, Raio L, Dreher E, Mueller MD (2006) PAPP-A and osteoprotegerin, together with interleukin-8 and RANTES, are elevated in the peritoneal fluid of women with endometriosis. Am J Obstet Gynecol 195(1):103–108. doi:10.1016/j.ajog.2005.12.010\nHarada M, Osuga Y, Hirata T, Hirota Y, Koga K, Yoshino O, Morimoto C, Fujiwara T, Momoeda M, Yano T, Tsutsumi O, Taketani Y (2004) Concentration of osteoprotegerin (OPG) in peritoneal fluid is increased in women with endometriosis. Hum Reprod 19(10):2188–2191. doi:10.1093/humrep/deh412\nWang SH, Cao Z, Wolf JM, Van Antwerp M, Baker JR Jr (2005) Death ligand tumor necrosis factor-related apoptosis-inducing ligand inhibits experimental autoimmune thyroiditis. Endocrinology 146(11):4721–4726. doi:10.1210/en.2005-0627\nLub-de Hooge MN, de Vries EG, de Jong S, Bijl M (2005) Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis 64(6):854–858. doi:10.1136/ard.2004.029058\nKim JG, Kim H, Ku SY, Kim SH, Choi YM, Moon SY (2004) Association between human alpha 2-Heremans Schmidt glycoprotein (AHSG) polymorphism and endometriosis in Korean women. Fertil Steril 82(6):1497–1500. doi:10.1016/j.fertnstert.2004.05.089\nKim SH, Choi YM, Choung SH, Jun JK, Kim JG, Moon SY (2005) Vascular endothelial growth factor gene +405 C/G polymorphism is associated with susceptibility to advanced stage endometriosis. Hum Reprod 20(10):2904–2908. doi:10.1093/humrep/dei146\nChae SJ, Kim H, Jee BC, Suh CS, Kim SH, Kim JG (2008) Tumor necrosis factor (TNF)-TNF receptor gene polymorphisms and their serum levels in Korean women with endometriosis. Am J Reprod Immunol 60(5):432–439\nFernandez V, Jares P, Bea S, Salaverria I, Guino E, de Sanjose S, Colomer D, Ott G, Montserrat E, Campo E (2004) Frequent polymorphic changes but not mutations of TRAIL receptors DR4 and DR5 in mantle cell lymphoma and other B-cell lymphoid neoplasms. Haematologica 89(11):1322–1331\nFisher MJ, Virmani AK, Wu L, Aplenc R, Harper JC, Powell SM, Rebbeck TR, Sidransky D, Gazdar AF, El-Deiry WS (2001) Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res 7(6):1688–1697\nFrank B, Shanmugam KS, Beckmann L, Hemminki K, Brenner H, Hoffmeister M, Chang-Claude J, Burwinkel B (2006) Death receptor 4 variants and colorectal cancer risk. Cancer Epidemiol Biomark Prev 15(10):2002–2005. doi:10.1158/1055-9965.EPI-06-0053\nHazra A, Chamberlain RM, Grossman HB, Zhu Y, Spitz MR, Wu X (2003) Death receptor 4 and bladder cancer risk. Cancer Res 63(6):1157–1159\nKikuchi S, Miyagishi R, Fukazawa T, Yabe I, Miyazaki Y, Sasaki H (2005) TNF-related apoptosis inducing ligand (TRAIL) gene polymorphism in Japanese patients with multiple sclerosis. J Neuroimmunol 167(1–2):170–174. doi:10.1016/j.jneuroim.2005.06.021\nYan X, Xu L, Qi J, Liang X, Ma C, Guo C, Zhang L, Sun W, Zhang J, Wei X, Gao L (2009) sTRAIL levels and TRAIL gene polymorphisms in Chinese patients with fatty liver disease. Immunogenetics 61(8):551–556. doi:10.1007/s00251-009-0389-4\nAmerican Society for Reproductive Medicine (1997) Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril 67(5):817–821\nLangdahl BL, Carstens M, Stenkjaer L, Eriksen EF (2002) Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures. J Bone Miner Res 17(7):1245–1255. doi:10.1359/jbmr.2002.17.7.1245\nYamada Y, Ando F, Niino N, Shimokata H (2003) Association of polymorphisms of the osteoprotegerin gene with bone mineral density in Japanese women but not men. Mol Genet Metab 80(3):344–349. doi:10.1016/S1096-7192(03)00125-2\nMartinez-Ferrandis JI, Rodriguez-Lopez R, Milne RL, Gonzalez E, Cebolla E, Chirivella I, Zamora P, Arias JI, Palacios S, Cervantes A, Diez O, Benitez J, Armengod ME (2007) Polymorphisms in TRAIL receptor genes and risk of breast cancer in Spanish women. Cancer Biomark 3(2):89–93\nHorak P, Pils D, Roessler M, Tomek S, Elandt K, Zeillinger R, Zielinski C, Krainer M (2005) Common death receptor 4 (DR4) polymorphisms do not predispose to ovarian cancer. Gynecol Oncol 97(2):514–518. doi:10.1016/j.ygyno.2005.01.021\nZhao HY, Liu JM, Ning G, Zhao YJ, Zhang LZ, Sun LH, Xu MY, Uitterlinden AG, Chen JL (2005) The influence of Lys3Asn polymorphism in the osteoprotegerin gene on bone mineral density in Chinese postmenopausal women. Osteoporos Int 16(12):1519–1524. doi:10.1007/s00198-005-1865-9\nWynne F, Drummond F, O’Sullivan K, Daly M, Shanahan F, Molloy MG, Quane KA (2002) Investigation of the genetic influence of the OPG, VDR (Fok1), and COLIA1 Sp1 polymorphisms on BMD in the Irish population. Calcif Tissue Int 71(1):26–35. doi:10.1007/s00223-001-2081-z\nAcknowledgments\nThis study was supported by a National Research Foundation of Korea Grant funded by the Korean Government (2010-0015704).\nConflict of Interest\nThe authors declare that there are no conflicts of interest.\nAuthor information\nAuthors and Affiliations\nCorresponding authors\nAdditional information\nJ. H. Kim and J. G. Kim contributed equally to this work.\nRights and permissions\nAbout this article\nCite this article\nKim, H., Ku, SY., Suh, C.S. et al. Association between endometriosis and polymorphisms in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptor and osteoprotegerin genes and their serum levels. Arch Gynecol Obstet 286, 147–153 (2012). https://doi.org/10.1007/s00404-012-2263-0\nReceived:\nAccepted:\nPublished:\nIssue date:\nDOI: https://doi.org/10.1007/s00404-012-2263-0","source_license":"CC0","license_restricted":false}